Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients

References

• Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5–12
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123–35
   PubMed Web of Science ®Google Scholar
• Bassil N. Late-onset hypogonadism. Med Clin North Am 2011;95:507–23, x
   PubMed Web of Science ®Google Scholar
• Balzi D, Lauretani F, Barchielli A, et al. Risk factors for disability in older persons over 3-year follow-up. Age Ageing 2010;39:92–8
   PubMed Web of Science ®Google Scholar
• Hyde Z, Flicker L, Almeida OP, et al. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab 2010;95:3165–72
   PubMed Web of Science ®Google Scholar
• Travison TG, Nguyen AH, Naganathan V, et al. Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the concord health and ageing in men project. J Clin Endocrinol Metab 2011;96:2464–74
   PubMed Web of Science ®Google Scholar
• Cicero AF, Magni P, Lentini P, et al. Sex hormones and adipokines in healthy pre-menopausal, post-menopausal and elderly women, and in age-matched men: data from the Brisighella Heart study. J Endocrinol Invest 2011;34:e158–62
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828–37
   PubMed Web of Science ®Google Scholar
• Cao J, Chen TM, Hao WJ, et al. Correlation between sex hormone levels and obesity in the elderly male. Aging Male 2012;15:85–9
   PubMed Web of Science ®Google Scholar
• Cicero AF, Magni P, More M, et al. Metabolic syndrome, adipokines and hormonal factors in pharmacologically untreated adult elderly subjects from the Brisighella Heart Study historical cohort. Obes Facts 2012;5:319–26
   PubMedGoogle Scholar
• George JT, Millar RP, Anderson RA. Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. Neuroendocrinology 2010;91:302–7
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 2011;96:2643–51
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899–906
   PubMed Web of Science ®Google Scholar
• Legros JJ, Meuleman EJ, Elbers JM, et al. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009;160:821–31
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
   PubMed Web of Science ®Google Scholar
• Valenti G, Gontero P, Sacco M, et al. Harmonized Italian version of the Aging Males' Symptoms scale. Aging Male 2005;8:180–3
   PubMedGoogle Scholar
• Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–56
   PubMed Web of Science ®Google Scholar
• Marin P, Holmang S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res 1993;1:245–51
   PubMedGoogle Scholar
• Mårin P. Effects of androgens in men with the metabolic syndrome. Aging Male 1998;1:129–36
   Google Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1–7
   PubMedGoogle Scholar
• Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011;8:272–83
   PubMed Web of Science ®Google Scholar
• Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012;8:131–43
   PubMedGoogle Scholar
• Tribess S, Virtuoso Junior JS, Oliveira RJ. Physical activity as a predictor of absence of frailty in the elderly. Rev Assoc Med Bras 2012;58:341–7
   PubMed Web of Science ®Google Scholar
• Kalyani RR, Tian J, Xue QL, et al. Hyperglycemia and incidence of frailty and lower extremity mobility limitations in older women. J Am Geriatr Soc 2012;60:1701–7
   PubMed Web of Science ®Google Scholar
• Kohn FM, Schill WB. A new oral testosterone undecanoate formulation. World J Urol 2003;21:311–15
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Ishikawa T, Chiba K, Fujisawa M. Assessment of possible effects for testosterone replacement therapy in men with symptomatic late-onset hypogonadism. Andrologia 2011;43:52–6
   PubMedGoogle Scholar
• Makinen JI, Huhtaniemi I. Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies – a mini-review. Gerontology 2011;57:193–202
   PubMedGoogle Scholar
• Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004;151:415–24
   PubMed Web of Science ®Google Scholar
• Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351–61
   PubMed Web of Science ®Google Scholar
• Coward RM, Simhan J, Carson 3rd CC. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 2009;103:1179–83
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol 2012;212:71–84
   PubMed Web of Science ®Google Scholar
• Kiraly CL. Androgenic-anabolic steroid effects on serum and skin surface lipids, on red cells, and on liver enzymes. Int J Sports Med 1988;9:249–52
   PubMed Web of Science ®Google Scholar
• Gasser RW. [Androgen therapy from the viewpoint of the internal medicine physician]. Wien Med Wochenschr 2001;151: 444–7
   PubMedGoogle Scholar